Maddy, BL, and Cook, M. 2002. Pediatrics and the
legislature: suggestions for lobbying your legislature. J Pediatr
Children with Special Health Care Needs
Association for Maternal and Child Health Programs (AMCHP)
(click on Maternal and Child Health Topics: Listings A-G: CYSHCN in the left hand toolbar)
National Survey of Children with Special Health Care Needs
Asthma is a chronic lung condition characterized by ongoing inflammation of
the airways. In a person with asthma the airways are hyper-responsive to
a variety of environmental stimuli, or triggers, including specific inhalant
antigens, infectious agents, cold air, tobacco smoke, aerosolized chemicals,
dust, cockroaches, strong aromas, foods, and exercise. Such airway hyperactivity,
characterized by bronchial smooth muscle contraction, increased mucus secretion,
and edema with inflammation, results in obstruction of the airways.
The predominant clinical features of asthma are wheezing (a musical, high-pitched,
largely expiratory sound), coughing, and shortness of breath. Although asthma
can occur at any age, typical onset is within the first five years of life.
The clinical spectrum of asthma varies considerably. Some children with asthma
may have occasional, mild symptoms while others experience severe, life threatening
attacks every few months, but otherwise remain symptom free. Still others
have daily symptoms that interfere with their life-style.
The severity of asthma has been classified by the National Heart, Lung and
Blood Institute (NHLBI) into the four categories of mild intermittent, mild
persistent, moderate persistent, and severe persistent. The illness usually
improves during mid-childhood and adolescence, although asthma can continue
into adulthood. In many children and adolescents with asthma, pulmonary functions
are normal when they are symptom-free. However, there is a subset of asthmatics
who have chronic hyperinflation and/or decreased pulmonary flow rates, even
in the absence of symptoms.
Treatment and Management
The goals of therapy for asthma are to prevent the development of symptoms
and to reverse the symptoms when they occur. Achieving these goals requires
appropriate pharmacologic therapy along with appropriate measures of environmental
control. The pharmacotherapy of children with asthma may include a variety
of drugs that can be used simultaneously. The two major categories of medications
are relievers and controllers.
Relievers are used to treat acute symptoms of coughing, wheezing and shortness
of breath. They are usually short acting inhaled bronchodilators used on an
as needed basis. Any form of persistent asthma requires treatment with controller
medications that are long-term daily maintenance medications used to control
asthma symptoms and avoid exacerbations. Long-acting inhaled and oral anti-inflammatory
agents, inhaled and oral bronchodilators and oral leukotriene modifiers are
the most common classes of drugs currently used to control asthma symptoms.
Asthma is among the leading causes of acute and chronic illness in children.
It is estimated that up to 10 per cent of American children have asthma during
childhood. The disease is the most frequent admitting diagnosis in children’s
A child may be treated by a variety of practitioners in a variety of settings.
Often, primary care physicians will diagnose and manage asthma. Some children
are seen frequently in the emergency department and may need hospitalization.
Other children are partially managed in the school setting by school nurses.
Allergists or pulmonologists who often have the support of an interdisciplinary
team may treat those children who are more difficult to manage.
The NHLBI Guidelines specify which medications are appropriate for a given
level of severity. An action plan that is unique to each patient should be
developed by the clinician to guide the family in the response to the inevitable
exacerbations. Any therapy should fit the family setting to improve adherence
to therapy, provide the ability for normal exercise and daily function, and
minimize hospitalizations/emergency room visits.
There are several good websites regarding asthma. One of them is the
American Lung Association’s site: http://www.lungsusa.org (Click on diseases A-Z and search for asthma)
American Academy of Allergy, Asthma, & Immunology, American Academy
of Pediatrics, National Education and Prevention Program, National
Heart Lung and Blood Institute. Pediatric Asthma: Promoting Best Practice.
Guide for Managing Asthma in Children. (2004). Milwaukee, WI.
AAAAI web-site: http://www.aaaai.org
Lasley, M.V. (2003). New treatments for asthma. Pediatrics in Review, 24(7),
National Heart, Lung, and Blood Institute. (2002). Expert panel report 3: Guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program. (NIH Publication No. 08-4051). Bethesda, MD: US Department of Health and Human Services. http://www.nhlbi.nih.gov
National Heart, Lung, and Blood Institute. (2007). Expert panel report 3: Guidelines for the diagnosis and management of asthma summary report 2007. National Asthma Education and Prevention Program. (NIH Publication No. 08-5846). Washington DC: US Government Printing Office. http://www.nhlbi.nih.gov
[Back to Top]
Cystic Fibrosis (CF) is a genetic disorder that causes the body to produce
an abnormally thick, sticky mucus. This is due to the faulty transport of sodium
and chloride within cells lining organs such as the lungs and pancreas. The
thick mucus in the lungs can cause chronic infection and damage to the lungs.
This thick mucus also obstructs the pancreas, preventing enzymes from reaching
the intestines to help break down and digest food.
CF is the most common lethal genetic disease among whites, occurring once in
every 2,500 to 3,200 live births.1 (Among African Americans the
incidence is one in 115,000 births, among Asians one in 31,000, among Hispanics
one in 9,200, and among the Native American population one in 10,900).2 The
disease is an autosomal recessive disorder caused by an abnormality in the
cystic fibrosis transmembrane regulator (CFTR) protein. The result is an
increased level of sodium reabsorption and decreased chloride secretion.
In recent years great strides have been made in the understanding of the etiology,
pathophysiology and genetics of CF. In 1989 the CF gene was discovered on the
long arm of chromosome 7. The most common mutation is called 508 and accounts
for 67 per cent of CF alleles among whites.1 However, more than
600 CF gene mutations have been identified.4 These discoveries may
lead to improved treatment of CF, including gene therapy.
CF has a wide range of clinical manifestations with a variable pattern of onset
and a broad spectrum of severity. The disorder is characterized by widespread
dysfunction of the exocrine glands, so that they produce abnormally thick and
viscous mucus throughout the body. Numerous secondary complicating features
affect most organ systems. The predominant clinical manifestations are: (a)
Chronic obstructive infectious pulmonary disease caused by the abnormally thick
mucus secretions that completely or partially obstruct airways; (b) inability
to release pancreatic enzymes for digestion into the small intestine, and (c)
elevated sodium and chloride concentrations in sweat.1 The median
survival age in the United States is 31 years; it is difficult to estimate
life expectancy for young children due to recent advances in treatment.3
The pulmonary disease picture is a cycle (usually measured in years) of acute
and chronic bacterial pulmonary infection, excessive inflammation as well as
impaired ciliary function. This leads to excess mucus secretion and bronchial
obstruction, infection and inflammation resulting in bronchiectasis.7 Related
pulmonary complications of CF include nasal polyps, sinusitis, asthma, allergic
bronchopulmonary aspergillosis (ABPA) pneumothorax and hemoptysis.7
Exocrine pancreatic function may be completely abated, partially active, or
normal, although some compromise of exocrine function usually exists.1 Blockage
of pancreatic enzymes and inadequate bile acid and bicarbonate cause malabsorption
of fats, including essential fatty acids, proteins, and fat-soluble vitamins.
If untreated, the result is diarrhea, steatorrhea, azoterrhea, vitamin deficiencies,
As a person with CF ages and endocrine pancreatic function diminishes, glucose
intolerance may result. Diabetes mellitus develops in up to 15 percent of older
patients.5 Other potential gastrointestinal complications include
meconium ileus, intestinal obstruction, gallbladder disease, and biliary cirrhosis.
Women with CF have normal reproductive organs but
puberty and the onset of menstruation can be delayed by a few years.
Studies show that up to 20% of women with CF experience infertility.
One reason for this is the thick cervical mucus, which acts as a barrier
to sperm. However, many women with CF do conceive and give birth. In
such cases, the physical stress of the pregnant woman with CF and the
life expectancy of the mother are issues that must be addressed. Men
with CF have normal external reproductive organs, but again in some
cases, puberty is delayed a few years. The majority (97% to 98%) of
men with CF are infertile due to azospermia, caused by abnormalities
of the reproductive ducts essential for normal sperm production.6
Treatment and Management
Removal of the thick mucus from the lungs is an important
component of therapy to maintain optimal lung function. Various modes
of therapy are used to effect mucus removal. They include the following:
postural drainage with percussion, alternative airway clearance techniques
such as the Flutter® device, positive expiratory pressure (PEP),
active cycle of breathing technique (ACBT), mechanical vest, autogenic
drainage, and exercise therapy. Mucolytic agents may be used to augment
the removal of mucus.
The use of bronchodilator therapy is controversial, but patients with CF who
have documented airway hyper-reactivity may benefit from such therapy. Corticosteroid
therapy has a role in the treatment of allergic bronchopulmonary aspergillosis.
It may also be considered for infants with severe bronchiolitis and patients
with significant airway obstruction unresponsive to bronchodilators.7
Antibiotics may be used acutely or chronically and are usually selected on
the basis of the results of sputum cultures. They may be given as oral, inhaled
or intravenous formulations. Intravenous antibiotics are the treatment of choice
for the episodic acute pulmonary exacerbations of CF. Manifestations of an
exacerbation include increased cough, sputum production, and respiratory rate,
and significant weight loss, low-grade fever, fatigue and malaise. As the disease
progresses P. aeruginosa is the most frequent pathogen. The antibiotics selected
are often a combination of semisynthetic penicillin and an aminoglycoside such
as tobramycin, which have been shown to have synergistic effects against Pseudomonas
Most of the morbidity and nearly all of the mortality associated with CF are
caused by the progressive pulmonary disease. Pulmonary function deteriorates
over time eventually resulting in respiratory failure. At present the only
effective treatment or therapy for patients with end-stage CF and severe dysfunction
of both the heart and the lungs is a heart-lung transplant. This usually results
in marked improvement in lung function and no recurrence of the chronic lung
infections. This is a relatively new therapy and the long-term survival rates
For those with intestinal symptoms, oral replacement of pancreatic enzymes,
fat soluble vitamins (A, E, D, K) and high-calorie diet help control the symptoms
and improve nutritional status. Major nutritional emphasis is to provide adequate
calories to compensate for malabsorption and the higher metabolic rate caused
by infection and increased work of breathing. Additional medications that may
be used include antacids, H2 blockers, prokinetic agents, urosodeoxycholic
acid. Supplementary sodium chloride is needed in hot weather or with increased
Proper management of patients with CF requires a broad understanding of the
disease pathology and knowledge of the secondary physical, psychological, social,
and financial manifestations. This necessitates an interdisciplinary approach.
The interdisciplinary specialists at a CF Center coordinate ongoing CF care
of the chronically ill patient in the context of his or her family and community.
Open and clear communication among the child and family, primary care providers
and CF Center is an ongoing and essential process.1,5
The Cystic Fibrosis Foundation accredits its 115 CF Centers in the United States,
supports research, and maintains a national registry. Services that the CF
Centers provide include sweat testing, designation and evaluation of therapeutic
programs, education of family and child, instruction in pulmonary therapy and
nutrition, genetic, vocational, and financial counseling.
One of many websites about Cystic Fibrosis is: the National Cystic Fibrosis
Foundation site http://www.cff.org
- Schwartz RH. Cystic fibrosis. In: Hockelman RA, ed. Primary
Pediatric Care. 2nd ed. St. Louis: Mosby; 1992:1208-1215.
- Hamosh A, Fitz-Simmons SC, Macek M Jr, Knowles MR, Rosenstein BJ,
Cutting GR. Comparison of the clinical manifestations of cystic fibrosis
in black and white patients. J Pediatr. 1998;132:255-259.
- Wilfond BS, Taussig LM. Cystic fibrosis: General overview. In Taussig
LM, Landau LI, eds. Pediatric Respiratory Medicine. St Louis:
- MacLusky I, Levison H. Cystic fibrosis. In Chernick V, Boat TF,
eds. Kendig’s Disorders of the Respiratory Tract
in Children. 6th ed. Philadelphia: WB Saunders: 1998:838-882.
- Creveling S, Light M, Gardner P, Greene L. Cystic fibrosis, nutrition,
and the health care team. J Am Diet Assoc. 1997;10(Suppl
- Lemke AA, Facts on fertility. In: Ramsey BW, Hodson ME , et al. New
Insights into Cystic Fibrosis. Califon, NJ: Gardiner-Caldwell
- Fiel SB, Part G 4 Cystic fibrosis. In: Bone RC, Dantzker DR, George
RB, Matthay RA, Reynolds HY, eds. Pulmonary & Critical
Care Medicine, 1998 ed., Mosby-Year Book, Inc. 1998:1-12.
[Back to Top]